Johns Hopkins Doses Nasal Foralumab in MS Trial
Tiziana Life SciencesLife Sciences has initiated dosing at Johns Hopkins University, the third site in its Phase 2 trial...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Tiziana Life SciencesLife Sciences has initiated dosing at Johns Hopkins University, the third site in its Phase 2 trial...
Acumen Pharmaceuticals presented extended results from its plasma pTau217 assay used to screen participants in the Phase 2 ALTITUDE-AD...
CervoMed announced positive 16-week results from the extension phase of its Phase 2b RewinD-LB study of neflamapimod for dementia...
AC Immune announced positive interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein (a-syn) in early...
Connect Biopharma announced positive feedback from the FDA regarding its plan for two Phase 2 trials of rademikibart. The...
Microbot Medical announced that data from its ACCESS-PVI trial, evaluating the LIBERTY® Endovascular Robotic System for peripheral vascular interventions,...
Cerevance announced topline results from its Phase 2 ASCEND trial of solengepras, a non-dopaminergic drug candidate for early-stage, untreated...
Candel Therapeutics announced promising Phase 1b clinical trial results for CAN-2409 combined with nivolumab and standard care in newly...
Medera Inc. announced updated positive results from its Phase 1/2a clinical trial of SRD-002, a gene therapy for heart...
Advanced Medical Balloons (AMB) announced positive data from their HYDRA-PMCF study on hygh-tec®, a new polyurethane fecal management system...